company background image
ALTH

Theranexus Société Anonyme ENXTPA:ALTHX Stock Report

Last Price

€1.94

Market Cap

€8.9m

7D

15.6%

1Y

-84.3%

Updated

25 May, 2022

Data

Company Financials +
ALTHX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ALTHX Stock Overview

Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders.

Theranexus Société Anonyme Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Theranexus Société Anonyme
Historical stock prices
Current Share Price€1.94
52 Week High€13.88
52 Week Low€1.51
Beta2.66
1 Month Change-8.71%
3 Month Change-18.14%
1 Year Change-84.30%
3 Year Change-66.44%
5 Year Changen/a
Change since IPO-88.10%

Recent News & Updates

Nov 24
Is Theranexus Société Anonyme (EPA:ALTHX) A Risky Investment?

Is Theranexus Société Anonyme (EPA:ALTHX) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

May 17
Is Theranexus Société Anonyme (EPA:ALTHX) Weighed On By Its Debt Load?

Is Theranexus Société Anonyme (EPA:ALTHX) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

ALTHXFR PharmaceuticalsFR Market
7D15.6%3.3%-2.9%
1Y-84.3%17.6%-6.3%

Return vs Industry: ALTHX underperformed the French Pharmaceuticals industry which returned 17.6% over the past year.

Return vs Market: ALTHX underperformed the French Market which returned -6.3% over the past year.

Price Volatility

Is ALTHX's price volatile compared to industry and market?
ALTHX volatility
ALTHX Average Weekly Movement8.9%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement6.0%
10% most volatile stocks in FR Market10.1%
10% least volatile stocks in FR Market3.5%

Stable Share Price: ALTHX is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ALTHX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
201318Franck Mouthonhttps://www.theranexus.com

Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company’s lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain.

Theranexus Société Anonyme Fundamentals Summary

How do Theranexus Société Anonyme's earnings and revenue compare to its market cap?
ALTHX fundamental statistics
Market Cap€8.87m
Earnings (TTM)-€8.15m
Revenue (TTM)€25.00k

355.3x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALTHX income statement (TTM)
Revenue€25.00k
Cost of Revenue€5.59m
Gross Profit-€5.57m
Other Expenses€2.58m
Earnings-€8.15m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 27, 2022

Earnings per share (EPS)-1.78
Gross Margin-22,264.00%
Net Profit Margin-32,600.00%
Debt/Equity Ratio47.2%

How did ALTHX perform over the long term?

See historical performance and comparison

Valuation

Is Theranexus Société Anonyme undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


0.75x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALTHX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALTHX's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALTHX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French Pharmaceuticals industry average.

PE vs Market: ALTHX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALTHX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALTHX is good value based on its Price-To-Book Ratio (0.8x) compared to the FR Pharmaceuticals industry average (2.4x).


Future Growth

How is Theranexus Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALTHX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALTHX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALTHX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALTHX's revenue (81.3% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: ALTHX's revenue (81.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALTHX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Theranexus Société Anonyme performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-24.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALTHX is currently unprofitable.

Growing Profit Margin: ALTHX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALTHX is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.

Accelerating Growth: Unable to compare ALTHX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALTHX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).


Return on Equity

High ROE: ALTHX has a negative Return on Equity (-69.03%), as it is currently unprofitable.


Financial Health

How is Theranexus Société Anonyme's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALTHX's short term assets (€16.2M) exceed its short term liabilities (€2.8M).

Long Term Liabilities: ALTHX's short term assets (€16.2M) exceed its long term liabilities (€4.6M).


Debt to Equity History and Analysis

Debt Level: ALTHX has more cash than its total debt.

Reducing Debt: ALTHX's debt to equity ratio has reduced from 162.1% to 47.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALTHX has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALTHX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Theranexus Société Anonyme current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALTHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALTHX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALTHX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALTHX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALTHX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Franck Mouthon

4.67yrs

Tenure

€286,952

Compensation

Mr. Franck Mouthon serves as the Chairman and Chief Executive Officer of Theranexus société anonyme since September 26, 2017. Mr. Mouthon is also an Administrator of France Biotech. Mr. Mouthon has 15 year...


CEO Compensation Analysis

Compensation vs Market: Franck's total compensation ($USD306.41K) is about average for companies of similar size in the French market ($USD288.98K).

Compensation vs Earnings: Franck's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ALTHX's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: ALTHX's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.8%.


Top Shareholders

Company Information

Theranexus Société Anonyme's employee growth, exchange listings and data sources


Key Information

  • Name: Theranexus Société Anonyme
  • Ticker: ALTHX
  • Exchange: ENXTPA
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €8.867m
  • Shares outstanding: 4.57m
  • Website: https://www.theranexus.com

Number of Employees


Location

  • Theranexus Société Anonyme
  • 60 avenue Rockefeller
  • Pépinière Laennec
  • Lyon
  • Rhône-Alpes
  • 69008
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.